Liquid biopsy aims at simple, fast, cost-efficient, and less burdensome sample collection for cancer detection, screening, and disease monitoring; and comes with a much-appreciated clinical advantage of reduced patient morbidity and ease of longitudinal monitoring.
Growing demand for faster and earlier cancer diagnosis has brought global attention towards, CTC, a major biomarker in the liquid biopsy sample. CTC detection is a simple blood test which that allows for cancer diagnosis and has the potential to be a routine clinical practice for early cancer detection and screening.
Furthermore, advancement in technology has not only aided in the high-throughput, high-purity isolation of CTCs; but also with high specificity. The liquid biopsy market, specifically the global CTC market is estimated to show steady growth and register a healthy CAGR of 15.4% in the forecast period of 2019-2026.
The high prevalence of cancer incidence globally has had a significant impact on a preference
for minimally invasive methods for disease screening, diagnosis, and monitoring;
with the global liquid biopsy, the market projected to expand at a healthy CAGR of 23.12% by 2027.
Liquid biopsy aims at simple, fast, cost-efficient, and less burdensome sample collection for cancer detection, screening, disease monitoring;
and comes with a much-needed clinical advantage of longitudinal/real-time monitoring of disease prognosis or response to therapy.
It has the advantage of overcoming the sampling issues associated with conventional tissue biopsy including tumor region selection bias and
less representation of tumor heterogeneity.